Harnessing ECD cleavage of ALK for immunotherapy against neuroblastoma
Active Project Grant Awarded Last action
- Award ID
- HT94252410440
- Recipient
-
Institute Of Cancer Research: Royal Cancer Hospital (The) UEI KXJBJJGTZTU3
- Awarding agency
-
Defense Health Agency
Department of Defense
- Obligated
- $1,833,330
Award facts
- Assistance listing
- 12.420 Military Medical Research and Development
- Completion date 61% complete
- Place of performance
- Great Britain, United Kingdom
Award details come from USAspending.gov.
About this award
The federal Project Grant award, ID HT94252410440, was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to support the project "HARNESSING ECD CLEAVAGE OF ALK FOR IMMUNOTHERAPY AGAINST NEUROBLASTOMA". The $1,833,330.00 grant was awarded on June 1, 2024 to the Institute of Cancer Research: Royal Cancer Hospital (The) in the United Kingdom, with a project period through May 31, 2028. As the primary awardee, the Institute of Cancer Research will conduct research to develop immunotherapies targeting neuroblastoma, a type of childhood cancer, by harnessing the cleavage of the ALK protein. The Institute has previously received federal grant funding as a subawardee for cancer research projects, demonstrating its expertise in this area.
Quick answers
Who received award HT94252410440?
HT94252410440 was awarded to Institute Of Cancer Research: Royal Cancer Hospital (The) by Defense Health Agency (Department of Defense) on June 1, 2024.
How much is award HT94252410440 worth?
$1,833,330 has been obligated on HT94252410440.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award